Medical Professionals

Posted by on Dec 9, 2012 in slider | 0 comments

Medical Professionals

Medifocus develops and commercializes minimally invasive treatment systems used in treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostatic Hyperplasia (“BPH”).  The Company owns two technology platforms with comprehensive US and international patent protection:

1. The “Endo-thermotherapy Platform”, and
2. The “Adaptive Phased Array Microwave Focusing Platform”.

The Company has received regulatory approvals to complete the APA 1000’s pivotal Phase-III clinical trials, the final step before marketing approval. The U.S. FDA-approved Prolieve® System is a medical device based on endo-thermotherapy that both heats the prostate and dilates the prostatic urethra. The Prolieve® System is the only minimally invasive treatment option for the symptoms of enlarged prostate in men indicated by the FDA as an in office treatment alternative to drug therapy.  The Prolieve® System is a revenue generating product catering to the $8 billion non-surgical BPH drug market. The Company is currently focusing on marketing Prolieve® for the treatment of BPH and accelerating the APA 1000 breast cancer system’s Phase III study.